Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.57 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | VCP | P55072 | 2/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | EIF4E | P06730 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10922785 | 0.85 | CSNK2A2 (0.60) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP1A1 | |
| SCHEMBL3593040 | 0.84 | KDM4E (0.63) | KDM4EVCPCFTRALDH1A1HTT | |
| SCHEMBL21224686 | 0.83 | CSNK2A2 (0.60) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP1A1 | |
| SCHEMBL31173457 | 0.83 | CSNK2A2 (0.60) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP1A1 | |
| SCHEMBL3609594 | 0.83 | MAPT (0.48) | CSNK2A1ABL1VCPNPC1RAB9A | |
| SCHEMBL28911583 | 0.83 | MEN1 (0.59) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP1A1 | |
| SCHEMBL30118286 | 0.83 | MEN1 (0.59) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP1A1 | |
| Hydrochloric Acid SCHEMBL23704773 | 0.82 | CSNK2A2 (0.59) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP1A1 | |
| SCHEMBL3602570 | 0.82 | ABL1 (0.67) | ROCK2IDO1ABL1VCPCFTR | |
| SCHEMBL2393684 | 0.82 | HDAC3 (0.59) | ROCK2ABL1VCPNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| US-4696933-A | INHIBIT GASTRIC ACID SECRETION | ICI AMERICAS INC. (GB) | 1987-09-29 | — | — | US | disclosed |
| US-4496564-A | HISTAMINE H-2 ANTIGONISTS | ICI AMERICAS INC. (US) | 1985-01-29 | — | — | US | disclosed |
| US-4452985-A | 2-Guanyl-4-(substituted phenyl) thiazole derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-06-05 | — | — | US | disclosed |
| EP-0060093-A2 | Amide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | CSNK2A2 1615/4885CSNK2B 1210/4885CSNK2A1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.